Review highlights the diagnostic and prognostic importance of KL-6 in interstitial lung disease, suggesting improved patient outcomes.
Krebs von den Lungen-6 (KL-6) is a protein released by type II alveolar cells in response to injury or inflammatory stimuli. This release results in a significant increase in serum KL-6 levels, making it a useful biomarker for diagnosing and evaluating the prognosis of various respiratory diseases. It is particularly relevant for the diagnosis, stratification and treatment of interstitial lung disease (ILD). This review provides a concise review of the clinical value of serum KL-6 in the management of ILD, emphasizing its potential to improve patient care and outcomes.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: